Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.326
Sell
RSI(14)
29.933
Sell
STOCH(KDJ)(9,3,3)
12.197
Sell
ATR(14)
0.629
High Vlolatility
CCI(14)
-248.118
Oversold
Williams %R
95.865
Oversold
TRIX(12,20)
-0.234
Sell
StochRSI(14)
0.000
Sell
Mediwound Ltd
MDWD15.459USD
+0.409+2.72%
Market hours （ET）Quotes delayed by 15 min
34.64MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mediwound Ltd
Currency: USD Updated: 2026-03-27Key Insights
Mediwound Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 93 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.80.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mediwound Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Mediwound Ltd Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.96M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.96M.
Fairly Valued
The company’s latest PE is -7.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 6.94M shares, increasing 18.34% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.69K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
29.800
Target Price
+89.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Mediwound Ltd is 5.33, ranking 154 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.87M, representing a year-over-year decrease of 68.03%, while its net profit experienced a year-over-year decrease of 83.80%.
Score
Financials
4.72
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.98
Operational Efficiency
3.02
Growth Potential
4.42
Shareholder Returns
7.49
Mediwound Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Mediwound Ltd is 6.31, ranking 125 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -7.17, which is -64.45% below the recent high of -2.55 and -220.25% above the recent low of -22.96.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 93/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Mediwound Ltd is 8.33, ranking 41 out of 157 in the Pharmaceuticals industry. The average price target is 32.00, with a high of 39.00 and a low of 25.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
29.800
Target Price
+89.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Mediwound Ltd
MDWD
6
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Mediwound Ltd is 6.66, ranking 85 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 16.93 and the support level at 14.06, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
16.246
Sell
MA10
16.689
Sell
MA20
16.941
Sell
MA50
17.318
Sell
MA100
17.785
Sell
MA200
18.179
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Mediwound Ltd is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 54.04%, representing a quarter-over-quarter increase of 21.23%. The largest institutional shareholder is PRFDX, holding a total of 538.96K shares, representing 4.20% of shares outstanding, with 192.64% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Clal Biotechnology Industries Ltd
HOLD Alapkezelo Zrt
Investor AB
Yelin Lapidot Provident Funds Management Ltd
Rosalind Advisors, Inc.
BlackRock Institutional Trust Company, N.A.
Meitav Investment House Ltd
Deep Insight Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mediwound Ltd is 5.33, ranking 67 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.20
VaR
+5.59%
240-Day Maximum Drawdown
+32.33%
240-Day Volatility
+45.22%
Return
Best Daily Return
60 days
+4.62%
120 days
+6.21%
5 years
+35.08%
Worst Daily Return
60 days
-7.86%
120 days
-7.86%
5 years
-27.84%
Sharpe Ratio
60 days
-1.84
120 days
-0.46
5 years
+0.05
Risk Assessment
Maximum Drawdown
240 days
+32.33%
3 years
+34.31%
5 years
+82.04%
Return-to-Drawdown Ratio
240 days
-0.25
3 years
+0.42
5 years
-0.13
Skewness
240 days
+0.61
3 years
+1.83
5 years
+0.57
Volatility
Realised Volatility
240 days
+45.22%
5 years
+75.40%
Standardised True Range
240 days
+4.84%
5 years
+6.06%
Downside Risk-Adjusted Return
120 days
-62.51%
240 days
-62.51%
Maximum Daily Upside Volatility
60 days
+23.95%
Maximum Daily Downside Volatility
60 days
+31.89%
Liquidity
Average Turnover Rate
60 days
+0.61%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+18.51%
60 days
-16.64%
120 days
-9.16%
Peer Comparison
Pharmaceuticals
Mediwound Ltd
MDWD
6.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
